Impact of YAQ001 on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis.

In 30 seconds

This double-blind randomised controlled substudy examined YAQ001’s effects on the gut microbiome and exploratory markers of gut permeability and systemic inflammation in 28 patients with cirrhosis. Participants received YAQ001 (4 g once daily) or placebo, with assessments at baseline, 4 and 12 weeks. Overall microbiome alpha and beta diversity did not change. YAQ001 was associated with favourable shifts in selected bacterial abundances and virulence-related genes, and these changes were associated with reductions in permeability and inflammation markers. The study also found an in-vitro effect against Klebsiella pneumoniae biofilms; the authors describe the biomarker findings as trends.

Key findings

• Overall gut microbiome alpha and beta diversity remained unaltered.
• YAQ001 increased Adlercreutzia equolifaciens and decreased Klebsiella pneumoniae and Streptococcus mutans abundance.
• Antibiotic resistance genes decreased significantly in the YAQ001 group; changes were associated with reduced gut permeability and systemic inflammation markers.
• YAQ001 prevented Klebsiella pneumoniae biofilms in vitro.

Why it matters

The findings suggest that a gut-restricted adsorbent may influence selected microbial features linked to virulence and antimicrobial resistance, alongside exploratory biomarker changes in cirrhosis. These results add mechanistic evidence for further study, but do not establish that YAQ001 improves clinical outcomes or that the observed microbiome shifts translate into patient benefit.

What to keep in mind

The substudy included only 28 patients, and its microbiome and biomarker outcomes were exploratory. The reported changes do not establish clinical benefit; the biofilm finding was from in-vitro testing.